A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (β)-Thalassemia

Trial Profile

A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (β)-Thalassemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Beta-thalassaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms BELIEVE
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 30 Apr 2019 to 7 Jun 2025.
    • 09 Nov 2017 Planned primary completion date changed from 30 Sep 2018 to 24 Nov 2017.
    • 01 Jun 2017 According to a Celgene Corporation media release, the company expects to report top-line results from the study in the middle of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top